SBIR Phase I: Bioinformatics knowledge-based, universal library design for a non-immunoglobulin, protein-scaffold

SBIR 第一阶段：基于生物信息学知识的非免疫球蛋白、蛋白质支架的通用文库设计

• 批准号: 0740211
• 负责人: Guido Cappuccilli
• 金额: $ 9.82万
• 依托单位: Protelix Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0740211&HistoricalAwards=false
• 关键词: SBIR; Phase; Bioinformatics; knowledge; based

This Small Business Innovation Research (SBIR) Phase I research project aims to develop novel protein scaffolds for the targeting of specific molecules in vivo. The technology, based on site directed mutagenesis of specific residues, would enable the creation of a diverse library for screening against targets of interest. Specific targeting of molecules on the surface of cells is one of most powerful methods for delivery of drugs, or disruption of disease associated binding events. Human monoclonal antibodies are currently used to target cell surface receptors in order to treat some cancers and autoimmune disease. Use of aptamers is also showing promise for targeting specific molecules that are involved in disease processes. Yet, other methodologies are being developed to target molecules of interest. The proposed technology would provide a complementary therapeutic modality that could broaden the repertoire of the presently available target-specific, immunoglobulin-based, as well as other therapeutic modalities. As such, the technology may open the door to the treatment of many other types of diseases where molecule specific targeting is desirable.

这个小企业创新研究（SBIR）第一阶段研究项目旨在开发新型蛋白质支架，用于体内靶向特定分子。该技术基于特定残基的定点突变，将能够创建多样化的库来筛选感兴趣的靶点。 特异性靶向细胞表面上的分子是递送药物或破坏疾病相关结合事件的最有力的方法之一。 人类单克隆抗体目前用于靶向细胞表面受体，以治疗某些癌症和自身免疫性疾病。适体的使用也显示出靶向参与疾病过程的特定分子的前景。然而，正在开发其他方法来靶向感兴趣的分子。 所提出的技术将提供一种互补的治疗方式，其可以拓宽目前可用的靶特异性、基于免疫球蛋白的以及其他治疗方式的库。 因此，该技术可以为治疗许多其他类型的疾病打开大门，其中分子特异性靶向是期望的。